BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12566890)

  • 1. Efficacy of latanoprost additive therapy on uncontrolled glaucoma.
    Bayer A; Tas A; Sobaci G; Henderer JD
    Ophthalmologica; 2002; 216(6):443-8. PubMed ID: 12566890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose, or no pilocarpine therapy.
    Shin DH; McCracken MS; Bendel RE; Pearlman R; Juzych MS; Hughes BA; Schulz LL; Kim C; Baek NH
    Ophthalmology; 1999 Feb; 106(2):386-90. PubMed ID: 9951495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial.
    Maruyama K; Shirato S
    J Glaucoma; 2006 Aug; 15(4):341-5. PubMed ID: 16865013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of additive preoperative latanoprost treatment on the outcome of filtration surgery.
    Berthold S; Pfeiffer N
    Graefes Arch Clin Exp Ophthalmol; 2006 Aug; 244(8):1029-34. PubMed ID: 16341541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.
    Hatanaka M; Reis A; Sano ME; Susanna R
    J Glaucoma; 2010; 19(5):331-5. PubMed ID: 19730119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effects of latanoprost (Xalatan) and unoprostone (Rescula) in patients with open-angle glaucoma and suspected glaucoma.
    Sponsel WE; Paris G; Trigo Y; Pena M
    Am J Ophthalmol; 2002 Oct; 134(4):552-9. PubMed ID: 12383812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of diurnal intraocular pressure control in primary open-angle patients treated with latanoprost compared with surgically treated glaucoma patients: a prospective trial.
    Mansouri K; Orguel S; Mermoud A; Haefliger I; Flammer J; Ravinet E; Shaarawy T
    Br J Ophthalmol; 2008 Mar; 92(3):332-6. PubMed ID: 18211927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma.
    Nagar M; Ogunyomade A; O'Brart DP; Howes F; Marshall J
    Br J Ophthalmol; 2005 Nov; 89(11):1413-7. PubMed ID: 16234442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost.
    Tamer C; Oksüz H
    Ophthalmic Res; 2007; 39(1):24-31. PubMed ID: 17164574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraocular pressure after replacement of current dual therapy with latanoprost monotherapy in patients with open angle glaucoma.
    Pillunat LE; Larsson LI;
    Br J Ophthalmol; 2003 Dec; 87(12):1492-6. PubMed ID: 14660460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.
    Gandolfi SA; Cimino L
    Ophthalmology; 2003 Mar; 110(3):609-14. PubMed ID: 12623831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
    Walters TR; DuBiner HB; Carpenter SP; Khan B; VanDenburgh AM;
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraocular Pressure Lowering Effect of Latanoprost as First-line Treatment for Glaucoma.
    Aspberg J; Heijl A; Jóhannesson G; Lindén C; Andersson-Geimer S; Bengtsson B
    J Glaucoma; 2018 Nov; 27(11):976-980. PubMed ID: 30113517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraocular pressure control and fluctuation: the effect of treatment with selective laser trabeculoplasty.
    Nagar M; Luhishi E; Shah N
    Br J Ophthalmol; 2009 Apr; 93(4):497-501. PubMed ID: 19106150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of latanoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma.
    Oh JY; Park KH
    Korean J Ophthalmol; 2005 Dec; 19(4):297-301. PubMed ID: 16491821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma.
    Mastropasqua L; Carpineto P; Ciancaglini M; Gallenga PE
    Ophthalmology; 1999 Mar; 106(3):550-5. PubMed ID: 10080213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of latanoprost monotherapy treatment in primary open-angle glaucoma].
    Martínez García A; Pérez García R
    Arch Soc Esp Oftalmol; 2002 May; 77(5):269-74. PubMed ID: 12023746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the efficacy of latanoprost vs timolol using an alternate efficacy parameter: the intervisit intraocular pressure range.
    Varma R; Hwang LJ; Grunden JW; Bean GW; Sultan MB
    Am J Ophthalmol; 2009 Aug; 148(2):221-6. PubMed ID: 19427617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness of latanoprost for the treatment of pediatric glaucoma.
    Enyedi LB; Freedman SF; Buckley EG
    J AAPOS; 1999 Feb; 3(1):33-9. PubMed ID: 10071899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.